A new cancer drug has shown promising results in Phase 1 trials after blocking the growth of tumours in more than half of patients who did not receive any other treatment,media BGR reported. The drug, known as berzosertib, is part of a “precision medicine” therapy for specific genetic or genetic changes. Berzosertib works best when combined with conventional chemotherapy. The latter can destroy cancer cells, but have side effects throughout the body, while berzosertib prevents tumor cells from healing without affecting other healthy cells.
There are many kinds of malignant tumors, which affect the body in different ways, and the treatment process has its particularity. Depending on the diagnosis, some patients may have a greater chance of survival from cancer than others. Various factors affect the course and treatment of the disease. The faster you diagnose cancer, the easier it may be to treat and cure, but even so, patients may be at risk of recurrence.
There is no universal drug to treat cancer, but scientists have developed a new compound that could be close to that goal. The drug, called berzosertib, can stop cancer cells from repairing themselves and continuing to grow in the body. This is not a payload provided by Berzosertib to destroy cells – patients still need traditional chemotherapy. According to a new trial, adding berzosertib can increase the chances of success.
According to bbc News, according to a trial conducted by Cancer Research UK (ICR) and the Royal Marsden NHS Foundation Trust, more than half of the 40 patients had their tumours stopped growing after receiving the drug, with the first phase designed to test the safety of the drug, which needs more stages before Berzosertib is approved. The first stage includes patients with advanced tumors, and other treatments are ineffective. The next stage is already in progress.
Scientists say the drug blocks a protein involved in DNA repair that prevents cancer cells from recovering. This is part of a treatment concept called “precision medicine” that targets specific genetic or genetic changes. Unlike chemotherapy, the drug is only aimed at tumor cells, not healthy cells.
Scientists say the clinical response to stage 1 is unusual and further tests are needed to prove the drug’s effectiveness. Still, berzosertib seems to have worked, even if it can’t be touted as a “game-changing” drug. A patient with advanced bowel cancer who discovered his tumour had disappeared after using Berzosertib, remained cancer-free for two years. Another ovarian cancer patient had her tumour shrunk after combining chemotherapy with drugs. The trial phase may last much longer than other clinical trials.
“Nevertheless, the unusually strong effects of berzosertib, especially with conventional chemotherapy, give us reason to be optimistic about the results of subsequent studies. Dr Darius Wider told BBC News.